Περίληψη:
Background: To evaluate the long-term cost-effectiveness of liraglutide
versus sitagliptin or exenatide, added to oral antidiabetic drug mono-or
combination therapy respectively, in patients with Type 2 diabetes in
Greece.
Methods: The CORE Diabetes Model, a validated computer simulation model,
was adapted to the Greek healthcare setting. Patient and intervention
effects data were gathered from a clinical trial comparing liraglutide
1.2 mg once daily vs. sitagliptin 100 mg once daily, both combined with
metformin, and a clinical trial comparing liraglutide 1.8 mg once daily
vs. exenatide 10 mu g twice daily, both as add-on to metformin,
glimepiride or both. Direct costs were reported in 2013 Euros and
calculated based on published and local sources. All future outcomes
were discounted at 3.5% per annum, and the analysis was conducted from
the perspective of a third-party payer in Greece.
Results: Over a patient’s lifetime, treatment with liraglutide 1.2 mg
vs. sitagliptin drove a mean increase in discounted life expectancy of
0.13 (SD 0.23) years and in discounted quality-adjusted life expectancy
of 0.19 (0.16) quality-adjusted life years (QALYs), whereas therapy with
liraglutide 1.8 mg vs. exenatide yielded increases of 0.14 (0.23) years
and 0.19 (0.16) QALYs respectively. As regards lifetime direct costs,
liraglutide 1.2 mg resulted in greater costs of is an element of 2797
(is an element of 1468) versus sitagliptin, and so did liragluti de 1.8
mg compared with exenatide (is an element of 1302 [is an element of
1492]). Liraglutide 1.2 and 1.8 mg doses were associated with
incremental cost effectiveness ratios of is an element of 15101 and is
an element of 6818 per QALY gained, respectively.
Conclusions: Liraglutide is likely to be a cost-effective option for the
treatment of Type 2 diabetes in a Greek setting.
Συγγραφείς:
Tzanetakos, Charalampos
Melidonis, Andreas
Verras, Christos and
Kourlaba, Georgia
Maniadakis, Nikos
